News
DARE
0.8428
-0.96%
-0.0082
Daré Bioscience Faces Nasdaq Minimum Bid Price Noncompliance
TipRanks · 1d ago
Daré Bioscience Says It Received Nasdaq Minimum Bid Price Deficiency Notice, Has Until March 29, 2027 To Regain Compliance
Benzinga · 1d ago
Daré Bioscience Releases Updated Investor Corporate Presentation
TipRanks · 2d ago
Dare Bioscience announces issuance of patent for DARE-HPV program
TipRanks · 5d ago
Daré Bioscience Receives U.S. Patent For Its Pharmaceutical Compositions Formulated For Topical Application Comprising Lopinavir, Ritonavir To Treat Cervical Pathologies
Benzinga · 5d ago
Weekly Report: what happened at DARE last week (0921-0925)?
Weekly Report · 5d ago
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
Barchart · 5d ago
Analysts’ Top Healthcare Picks: IN8bio (INAB), Daré Bioscience (DARE)
TipRanks · 09/22 10:00
Weekly Report: what happened at DARE last week (0914-0918)?
Weekly Report · 09/21 09:58
Daré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure
NASDAQ · 09/14 14:34
Dare Bioscience publishes results from Sildenafil Cream study
TipRanks · 09/14 13:05
Daré Bioscience Announces Publication Of Results From A Phase 1 Clinical Study Evaluating Safety And Systemic Pharmacokinetics Of Topical Sildenafil Cream, 3.6%, In Healthy Adult Men In The Journal Sexual Medicine; At 71 Mg Topical Dose, Mean Maximum Plasma Concentration Of Sildenafil Was ~187-Fold Lower Than Following A 50 Mg Oral Dose
Benzinga · 09/14 12:55
Weekly Report: what happened at DARE last week (0907-0911)?
Weekly Report · 09/14 10:02
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
Barchart · 09/14 07:50
Daré Bioscience Updates Bylaws to Ease Shareholder Quorum
TipRanks · 09/11 21:24
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
Barchart · 09/11 05:55
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 09/09 21:06
Daré Bioscience Updates Investors with New Presentation
TipRanks · 09/09 13:31
Weekly Report: what happened at DARE last week (0831-0904)?
Weekly Report · 09/07 09:57
Dare Bioscience announces new $908,000 NIH funding award to advance DARE-PTB2
TipRanks · 08/31 13:00
More
Webull provides a variety of real-time DARE stock news. You can receive the latest news about Dare Bioscience Inc through multiple platforms. This information may help you make smarter investment decisions.
About DARE
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.